Discovery Platform

The discovery of novel therapeutic targets for liver fibrosis and HCC has been hampered by the complexity of disease biology and unsatisfactory model systems.

In contrast to classical drug discovery, the Alentis proprietary platform is unique and transforming by using a well characterized clinical gene expression signature predicting patientsā€˜ outcome as a read-out.

Discovery of several targets and compounds with validation in patient-derived in vivo and ex vivo models has confirmed the impact and value of the platform.

Given its simplicity, the platform allows fast-track and high-throughput discovery and development of novel and differentiated liver disease therapeutics.